Anti-dpp6 chimeric antigen receptor bearing regulatory t cells

Qizhi Tang; Jeffrey Bluestone; Emilie Ronin; Decio Eizirik; Nick Devoogdt

Anti-dpp6 chimeric antigen receptor bearing regulatory t cells

Qizhi Tang (Inventor), Jeffrey Bluestone (Inventor), Emilie Ronin (Inventor), Decio Eizirik (Inventor), Nick Devoogdt (Inventor)

Research output: Patent

Abstract

The present disclosure relates generally to regulatory T cells (Tregs) engineered to express a dipeptidyl aminopeptidase-like protein 6 (DPP6)-reactive chimeric antigen receptor (CAR). The engineered Tregs are suitable for use in immunotherapy regimens for autoimmune, inflammatory and degenerative diseases. In particular, the anti-DPP6 CAR expressing Tregs are suitable for treating or preventing autoimmune diseases of the pancreas or central nervous system.

Original language	English
Patent number	EP4236987
Publication status	Published - 2023

Handle.net

Persistent link

Cite this

@misc{9f027239a69b4c8f8f0d5fe39e724130,

title = "Anti-dpp6 chimeric antigen receptor bearing regulatory t cells",

abstract = "The present disclosure relates generally to regulatory T cells (Tregs) engineered to express a dipeptidyl aminopeptidase-like protein 6 (DPP6)-reactive chimeric antigen receptor (CAR). The engineered Tregs are suitable for use in immunotherapy regimens for autoimmune, inflammatory and degenerative diseases. In particular, the anti-DPP6 CAR expressing Tregs are suitable for treating or preventing autoimmune diseases of the pancreas or central nervous system.",

author = "Qizhi Tang and Jeffrey Bluestone and Emilie Ronin and Decio Eizirik and Nick Devoogdt",

year = "2023",

language = "English",

type = "Patent",

note = "EP4236987",

}

TY - PAT

T1 - Anti-dpp6 chimeric antigen receptor bearing regulatory t cells

AU - Tang, Qizhi

AU - Bluestone, Jeffrey

AU - Ronin, Emilie

AU - Eizirik, Decio

AU - Devoogdt, Nick

PY - 2023

Y1 - 2023

N2 - The present disclosure relates generally to regulatory T cells (Tregs) engineered to express a dipeptidyl aminopeptidase-like protein 6 (DPP6)-reactive chimeric antigen receptor (CAR). The engineered Tregs are suitable for use in immunotherapy regimens for autoimmune, inflammatory and degenerative diseases. In particular, the anti-DPP6 CAR expressing Tregs are suitable for treating or preventing autoimmune diseases of the pancreas or central nervous system.

AB - The present disclosure relates generally to regulatory T cells (Tregs) engineered to express a dipeptidyl aminopeptidase-like protein 6 (DPP6)-reactive chimeric antigen receptor (CAR). The engineered Tregs are suitable for use in immunotherapy regimens for autoimmune, inflammatory and degenerative diseases. In particular, the anti-DPP6 CAR expressing Tregs are suitable for treating or preventing autoimmune diseases of the pancreas or central nervous system.

UR - http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP4236987&F=0

M3 - Patent

M1 - EP4236987

ER -

Anti-dpp6 chimeric antigen receptor bearing regulatory t cells

Abstract

Handle.net

Other files and links

Fingerprint

FWOAL963: Evaluation of an anti-idiotype NanoCAR-T cell approach for the treatment of Multiple Myeloma

Cite this

Anti-dpp6 chimeric antigen receptor bearing regulatory t cells

Abstract

Handle.net

Other files and links

Fingerprint

Projects

FWOAL963: Evaluation of an anti-idiotype NanoCAR-T cell approach for the treatment of Multiple Myeloma

Cite this